Decentralised clinical trials are usually described as an access story. By moving visits out of specialist centres and into homes, local clinics and community settings, sponsors can reach patients who would otherwise be excluded by distance, travel burden or caregiver constraints. That is a genuine advance. But the harder challenge is not recruitment. It is safety oversight. When trial activities are distributed across homes, local healthcare providers and third-party logistics networks, pharmacovigilance, product accountability and data provenance have to be redesigned rather than bolted on.
That distinction sits close to the concerns recognised through the 2026 Global Healthcare Awards. Credible innovation in care delivery depends less on the sophistication of a digital tool than on whether the operating model around it is accountable, auditable and safe. A decentralised trial is a useful test case because it exposes the gap between patient-facing convenience and the governance that makes convenience trustworthy.
Safety Reporting When Visits Leave the Site
In a conventional trial, adverse-event capture is anchored to a physical site. Participants are seen by staff who know the protocol, the investigational product and the reporting timelines. The safety narrative is built through familiar routines: scheduled visits, structured assessments, documented follow-up and a clear line of clinical responsibility.
Decentralisation fragments that routine. A participant may be monitored at home by a home-care nurse, seen at a local clinic by a clinician who is not a trial investigator, and asked to complete an electronic diary between visits. Each of those touchpoints can generate safety information. Each can also lose it.
The practical consequence is that adverse-event capture becomes dependent on clear patient instructions, unambiguous escalation pathways and reliable follow-up. Patients need to know what symptoms matter, who to contact and how quickly. Home-care staff need to understand what to report and to whom. Local clinicians need a route into the trial team when they see something unexpected. None of this is guaranteed by a smartphone app or a telehealth platform.
There is also a follow-up problem. Distributed models can make it easier to enrol patients, but harder to keep them under observation. Missed contacts, disconnected participants and incomplete diaries all weaken the safety record. Sponsors and sites therefore need to design monitoring around the risk of absence, not just the convenience of remote contact.
Chain of Custody for Products and Samples
Direct-to-patient shipment of investigational products introduces a set of controls that are easier to take for granted inside a trial site. Temperature control, handling instructions, receipt confirmation, reconciliation of unused product and arrangements for return or destruction all have to be documented. When a courier hands a package to a patient, the chain of custody extends into a setting the sponsor does not control.
That does not make direct-to-patient shipment unsafe. It makes it an accountability problem. The record must show what was shipped, when it arrived, how it was stored and what happened to any remaining product. If a shipment is delayed, left in the wrong place or exposed to unsuitable conditions, the trial team needs a way to detect it and decide whether the participant can continue.
Remote sample collection raises similar questions. A sample taken at home may pass through a phlebotomist, a courier and a laboratory before it is analysed. Stability windows, labelling, packaging and handover all matter. The audit trail has to be strong enough to show that the sample was collected, transported and processed within the conditions the protocol requires. Without that, the data may exist but cannot be relied upon.
Provenance of Patient-Generated Data
Wearables, electronic diaries and telehealth visits generate a growing share of trial data. These tools can improve the granularity of monitoring and reduce the burden of travel. They also create a provenance problem. A heart-rate reading, a symptom score or a video-recorded assessment is only useful if the sponsor and the regulator can establish where it came from, how it was captured and whether it has been altered.
Documented provenance means knowing the device, the software version, the time of collection and whether the entry was made by the patient, a caregiver or a clinician. It means having validation and monitoring arrangements that are proportionate to the risk. A diary entry used to support a primary endpoint is not the same as a step count used for context. The level of scrutiny should reflect that difference.
Provenance is also a clinical safety issue. If a wearable alerts on a concerning rhythm, the trial needs a pathway for that signal to reach a clinician who can act on it. If a patient reports a symptom through a portal, the report cannot sit in a queue without an owner. Data quality and safety oversight are not separate workstreams; they meet in the same record.
Governance Across a Network of Parties
Decentralised trials distribute roles as well as activities. A sponsor may contract a site, a home-care provider, a logistics vendor and a technology supplier. Each has a part to play in safety reporting, product accountability or data management. The risk is that responsibility becomes assumed rather than assigned.
Governance therefore has to be explicit. Pharmacovigilance agreements should define who receives safety information, who assesses it and who reports it within the required timelines. Quality agreements should set out oversight of vendors, escalation routes and arrangements for audit. Trial sites need to know which decisions remain with the investigator and which can be delegated. Home-care providers need to understand the boundary between routine care and trial-related activity.
This is not a paperwork exercise. When an adverse event occurs at home, the response depends on someone recognising it, someone else being contactable and a clinician having the authority to act. Clear roles make that chain work. Unclear roles make it fragile.
Equity and Support Are Operational Questions
Decentralised models are often justified by their potential to widen access. That potential is real, but it is not automatic. Digital access, training, caregiver burden and local healthcare capacity all affect whether a participant can take part safely. A patient who cannot use the diary, lacks reliable connectivity or cannot reach a local clinic is not simply a recruitment statistic. They are a safety-reporting gap.
Support is therefore an operational control. Training, plain-language instructions, alternative contact routes and practical help with devices are not add-ons. They determine whether safety information reaches the trial team and whether follow-up happens. Inclusive design also means recognising that home environments differ and that local clinical capacity varies. A model that works in one setting may not transfer safely to another.
The 2026 Global Healthcare Awards focus on practical innovation that improves care without compromising safety or accountability. Decentralised trials fit that agenda only when the operating model is designed for the distributed setting. The question is not whether remote visits and direct-to-patient shipping are possible. It is whether the safety record, the chain of custody and the data trail remain robust when the trial is no longer contained by a site. That is the pharmacovigilance test.
